Screening for chronic kidney disease

BMJ (Online)

Volumn 341, Issue 7781, 2010, Pages 1004-

  Kiberd, Bryce ^a,b  

^a Department of Medicine ^*  (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER SCREENING; CHRONIC KIDNEY DISEASE; DISEASE COURSE; EDITORIAL; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE; MAMMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT;

EARLY DIAGNOSIS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 78349243326     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c5734     Document Type: Editorial

References (11)

1. Manns B, Hemmelgarn B, Tonelli M, Flora A, Chiasson TC, Dong J, et al. Population based screening for chronic kidney disease: cost effectiveness study. BMJ 2010;c5869.
2. Quanstrum KH, Hayward RA. Lessons from the mammography wars. N Engl J Med 2010;363:1076-9.
3. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010;303:423-9.
4. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.
5. De Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: public health perspectives. J Am Soc Nephrol 2006;17:2120-6.
6. Hoerger TJ, Wittenborn JS, Segel JE, Burrows NR, Imai K, Eggers P, et al; Centers for Disease Control and Prevention CKD Initiative. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis 2010;55:463-73.
7. Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003;290:3101-14.
8. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-47.
9. Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004;110:2809-16.
10. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53.
11. Archibald G, Bartlett W, Brown A, Christie B, Elliott A, Griffith K, et al. UK Consensus Conference on Early Chronic Kidney Disease, 6 and 7 February 2007. Nephrol Dial Transplant 2007;22:2455-7.